General MedicationsORALHigh Alert

Eczemol

POTASSIUM BROMIDE, NICKEL SULFATE, AND SULFUR

Standard Dose

DOSAGE AND ADMINISTRATION Absorption of nickel sulphate is variable among individuals. For maximum absorption, tablets should be taken orally at the beginning of the day (or any convenient time after having taken nothing but water for at least 7 hours). Take nothing but water for one hour after taking medication to aid absorption. Kg lbs Starting dose Max Daily dose 5-11 11-25 ¼ ½ 12-22 26-50 ½ 1 23-45 51-100 1 2 46-68 101-150 2 4 69-90 151-200 3 6 91+ 201+ 4 8 In the setting of renal impairment Dosage should be adjusted and serum nickel and bromide levels should be followed. Steady state trough level should be drawn prior to ingesting the day's dose after one week of dosing or at appropriate intervals. Target trough serum nickel level is 20-40 mcg/L. (Caution: post dose peak levels are unreliable.) Treatment duration depends on the individual. Increase dose as needed on a monthly basis. Try b.i.d. dosing (upon rising and at bedtime) if max dose (see above ) is not effective; do not exceed max daily dose. Maintenance phase In order to maintain symptomatic relief, medication may be continued at the same or reduced initial phase dose level.

Max Dose

See official label

Primary Use

INDICATIONS ECZEMOL ® is indicated for the treatment of moderate to severe eczema and atopic dermatitis.

Summary

Indications and usage INDICATIONS ECZEMOL ® is indicated for the treatment of moderate to severe eczema and atopic dermatitis.

It has been found to work well with a variety of combination therapies.

Structured Monograph

Clinical summary

Indications and usage INDICATIONS ECZEMOL ® is indicated for the treatment of moderate to severe eczema and atopic dermatitis. It has been found to work well with a variety of combination therapies. Dosage and administration DOSAGE AND ADMINISTRATION Absorption of nickel sulphate is variable among individuals. For maximum absorption, tablets should be taken orally at the beginning of the day (or any convenient time after having taken nothing but water for at least 7 hours). Take nothing but water for one hour after taking medication to aid absorption. Kg lbs Starting dose Max Daily dose 5-11 11-25 ¼ ½ 12-22 26-50 ½ 1 23-45 51-100 1 2 46-68 101-150 2 4 69-90 151-200 3 6 91+ 201+ 4 8 In the setting of renal impairment Dosage should be adjusted and serum nickel and bromide levels should be followed. Steady state trough level should be drawn prior to ingesting the day's dose after one week of dosing or at appropriate intervals. Target trough serum nickel level is 20-40 mcg/L. (Caution: post dose peak levels are unreliable.) Treatment duration depends on the individual. Increase dose as needed on a monthly basis. Try b.i.d. dosing (upon rising and at bedtime) if max dose (see above ) is not effective; do not exceed max daily dose. Maintenance phase In order to maintain symptomatic relief, medication may be continued at the same or reduced initial phase dose level. Warnings and cautions WARNING Do not use if imprinted seal under bottle cap is missing or broken. Do not use if pregnant or nursing. If allergic to nickel or metal objects such as jewelry or if there is a history of blistering hand eczema, see PRECAUTIONS for hypersensitivity information. Lactose intolerant patients may have gastrointestinal difficulty. This has very rarely been reported at the doses used. Drug interactions Drug interactions There are no known drug interactions. Pregnancy Pregnancy Pregnancy category C Animal reproduction studies have not been conducted with ECZEMOL ® . ECZEMOL ® should not be given to a pregnant woman.

Monitoring

• WARNING Do not use if imprinted seal under bottle cap is missing or broken.
• Do not use if pregnant or nursing.
• If allergic to nickel or metal objects such as jewelry or if there is a history of blistering hand eczema, see PRECAUTIONS for hypersensitivity information.
• Lactose intolerant patients may have gastrointestinal difficulty.

Interaction Notes

• Drug interactions There are no known drug interactions.